References
- Group USCSW. U. S. Cancer statistics data visualizations tool, based on 2022 submission data. 2023 [cited 2024 Jan 2]. Available from: https://www.cdc.gov/cancer/dataviz
- Tewari K, Sill M, Long H, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654–1663. doi: 10.1016/S0140-6736(17)31607-0
- Marabelle A, Le D, Ascierto P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. doi: 10.1200/JCO.19.02105
- Monk B, Colombo N, Tewari K, et al. First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. J Clin Oncol. 2023;41(36):5505–5511. doi: 10.1200/JCO.23.00914
- Broderick J. Pembrolizumab granted FDA approval for PD-L1+ cervical cancer. [cited 2024 Mar 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s034lbl.pdf
- Lorusso D, Xiang Y, Colombo N, et al. 254TiP ENGOT-cx11/KEYNOTE-A18: a phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. Ann Oncol. 2020;31:S1341–42. doi: 10.1016/j.annonc.2020.10.248
- Tewari K, Monk B, Vergote I, et al. EMPOWER-Cervical 1/GOG-3016/ENGOT-Cx9. N Engl J Med. 2022;386(6):544–555. doi: 10.1056/NEJMoa2112187
- Abu-Rustum N, Yashar C, Arend R, et al. NCCN guidelines(R) insights: cervical cancer, (version 1). 2024. J Natl Compr Cancer Network. 2023;21(12):1224–1233. doi: 10.6004/jnccn.2023.0062
- Coleman L, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology. 2021;22(5):609–619. doi: 10.1016/S1470-2045(21)00056-5
- Administration, F.D.A. FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. FDA Approved Drugs; 2021 [cited 2024 Apr 2]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer
- Pfizer. Paclitaxel injection, USP adverse reactions. Pfizer medical information. 2023 [cited 2024 Nov 2]. Available from: https://www.pfizermedicalinformation.com/paclitaxel/adverse-reactions
- Kim S, Ursell P, Coleman R, et al. Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol. 2022;165(2):385–392. doi:10.1016/j.ygyno.2022.02.010
- Zhao X, Cheng C, Gou J, et al. Expression of tissue factor in human cervical carcinoma tissue. Exp Ther Med. 2018;16(5):4075–4081. doi: 10.3892/etm.2018.6723
- Bogani G, Coleman R, Vergote I, et al. Tisotumab vedotin in recurrent or metastatic cervical cancer. Curr Probl Cancer. 2023;47(3):100952. doi:10.1016/j.currproblcancer.2023.100952
- Vergote I, Nieuwenhuysen E, O’Cearbhaill R, et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205/GOG-3024/ENGOT-cx8 study. J Clin Oncol. 2023;41(36):5536–5549.